The two most comprehensive sublingual combination ED formulas compared — four ingredients vs three, and what the difference actually means in practice.
| Attribute | MEDVi Quad | Rugiet Ready |
|---|---|---|
| Formula | 4-in-1 | 3-in-1 |
| Sildenafil | ✓ | ✓ |
| Tadalafil | ✓ | ✓ |
| Vardenafil | ✓ (unique) | — |
| Apomorphine | ✓ | ✓ |
| Format | Sublingual liquid | Sublingual lozenge |
| Onset | 10–15 minutes | ~15 minutes |
| Duration | Up to 36 hours | Up to 36 hours |
| Dosing tiers | Clinician-set | 4 tiers (Low–Maximum) |
| Price | From $119/mo | 15% off w/ ET2026 |
| User base | Growing | 300,000+ users |
MEDVi Quad adds vardenafil to the standard sildenafil + tadalafil + apomorphine combination. Vardenafil is a selective PDE5 inhibitor with a slightly faster onset than sildenafil and — critically — no inhibition of PDE6, meaning it doesn't cause the temporary color vision disturbances that sildenafil occasionally produces.
Including all three PDE5 inhibitors creates overlapping vascular coverage with different selectivity profiles. Some men respond better to one PDE5 inhibitor than others, and combining all three reduces the risk that individual variation will limit the formula's effectiveness.
Rugiet's advantage is its dosing tier system and its larger documented user base. With four strength levels (Low through Maximum), Rugiet allows clinicians to start conservatively and escalate — a more gradual approach that suits men who prefer to step up carefully.
You want the most comprehensive ingredient profile available, have tried 3-in-1 formulas with partial results, or want the fastest possible sublingual onset.
You want a proven, established formula with a large user community and flexible dosing tiers. The tiered system is particularly valuable for men starting combination therapy for the first time.